Literature DB >> 8396479

Immunohistochemical analysis of expression of nm23-H1/nucleoside diphosphate kinase in human thyroid carcinomas: lack of correlation between its expression and lymph node metastasis.

W Luo1, K Matsuo, Y Nagayama, T Urano, K Furukawa, A Takeshita, T Nakayama, N Yokoyama, S Yamashita, M Izumi.   

Abstract

The nm23 gene that encodes nucleoside diphosphate (NDP) kinase has been proposed as a candidate tumor metastasis suppressor in rodent experimental carcinoma models and several types of human carcinomas. The present studies were designed to investigate, by immunohistochemical analysis, whether thyroid tissues express the nm23-H1/NDP kinase and, if so, whether the nm23-H1/NDP kinase expression is correlated to tumor metastasis suppressor potential in thyroid tumors. We found that normal thyroid epithelial cells were stained weakly but homogeneously by mouse monoclonal anti-nm23-H1/NDP kinase antibody. The staining intensity of the nm23-H1/NDP kinase in benign thyroid tumors tended to be weaker than that in normal thyroid tissues. In contrast, a series of malignant thyroid tumors expressed differently the nm23-H1/NDP kinase: the intensity of the nm23-H1/NDP kinase staining was stronger in 22 of 49 malignant tumors (45%), similar in 24 (49%), and weaker in 3 (6%) compared to that in normal tissues. The comparison of the staining intensity of the nm23-H1/NDP kinase in primary lesions of tumors with lymph node metastases and those without metastases revealed no statistically significant difference. In addition, there was also no significant difference in the nm23-H1/NDP kinase staining intensity of primary and metastatic lymph node lesions of tumors with lymph node metastases. These data indicate that the nm23-H1/NDP kinase may not be a good predictive marker for tumor regional metastatic potential in malignant thyroid tumors. We conclude that in thyroid tumors the nm23-H1/NDP kinase expression may be dissociated from metastasis suppressor activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396479     DOI: 10.1089/thy.1993.3.105

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  The mystery of nm23H1 in thyroid cancer.

Authors:  Y Shi; M Zou; N R Farid
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

2.  Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas.

Authors:  M Volm; J Mattern; R Koomägi
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

3.  Immunohistochemical detection of nm23/NDP kinase and cathepsin D in medullary carcinomas of the thyroid gland.

Authors:  R Holm; J Høie; O Kaalhus; J M Nesland
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  NM23 protein in neoplastic and nonneoplastic thyroid tissues.

Authors:  P Bertheau; A De La Rosa; P S Steeg; M J Merino
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

5.  Immunohistochemical analysis of nm23 protein expression in malignant bone tumors.

Authors:  Y Oda; H Walter; K Radig; I Röse; W Neumann; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.

Authors:  Choon-Yee Tan; Christina L Chang
Journal:  Lab Invest       Date:  2017-10-09       Impact factor: 5.662

7.  The association between nm23 gene expression and survival in patients with sarcomas.

Authors:  J A Royds; M H Robinson; T J Stephenson; R C Rees; C Fisher
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma.

Authors:  Marija Milkovic Perisa; Bozena Sarcevic; Koraljka Gall Troselj; Kresimir Grsic; Sanda Sitic; Sven Seiwerth
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.